Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...

Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's ...